GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adynxx Inc (OTCPK:ADYX) » Definitions » Revenue
中文

Adynxx (Adynxx) Revenue : $0.59 Mil (TTM As of Sep. 2019)


View and export this data going back to 1998. Start your Free Trial

What is Adynxx Revenue?

Adynxx's revenue for the three months ended in Sep. 2019 was $0.00 Mil. Its revenue for the trailing twelve months (TTM) ended in Sep. 2019 was $0.59 Mil. Adynxx's Revenue per Share for the three months ended in Sep. 2019 was $0.00. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2019 was $0.71.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.


Adynxx Revenue Historical Data

The historical data trend for Adynxx's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adynxx Revenue Chart

Adynxx Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.79 12.18 16.29 2.02 2.22

Adynxx Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.35 0.46 0.13 - -

Competitive Comparison of Adynxx's Revenue

For the Biotechnology subindustry, Adynxx's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Adynxx's Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adynxx's Revenue distribution charts can be found below:

* The bar in red indicates where Adynxx's Revenue falls into.



Adynxx Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Revenue for the trailing twelve months (TTM) ended in Sep. 2019 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Adynxx  (OTCPK:ADYX) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Adynxx Revenue Related Terms

Thank you for viewing the detailed overview of Adynxx's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Adynxx (Adynxx) Business Description

Traded in Other Exchanges
N/A
Address
100 Pine Street, Suite 500, San Francisco, CA, USA, 94111
Adynxx Inc is a United States-based clinical-stage biopharmaceutical company. It is focused on the development of a new class of therapeutics called transcription factor decoys and bringing to the market novel, disease-modifying products to address unmet needs in the treatment of pain and inflammation. Its pipeline includes brivoligide, a Phase 2 drug candidate intended to address postoperative pain, and AYX2, a pre-clinical candidate intended to treat chronic syndromes of pain, including both inflammatory and neuropathic pain.
Executives
Gregory J. Flesher director 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Donald C. Manning officer: CHIEF MEDICAL OFFICER C/O PACIRA BIOSCIENCES, INC., 5 SYLVAN WAY, SUITE 300, PARSIPPANY NJ 07054
Pierre Legault director P.O. BOX 1028, C/O STONE MANAGEMENT LLC, BERWYNE PA 19312
Domain Partners Viii, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Dp Viii Associates, L.p. 10 percent owner C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Eckard Weber director C/O DOMAIN ASSOCIATES, ONE PALO SQ, PRINCETON NJ 08542
Brian K Halak 10 percent owner C/O DOMAIN ASSOCIATES, ONE PALMER SQUARE, PRINCETON NJ 08542
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
James C Blair 10 percent owner 5880 PACIFIC CENTER BLVD, SAN DIEGO CA 92121-4204
Jesse I Treu 10 percent owner
Dennis Podlesak director C/O PENINSULA PHARMACEUTICALS, INC., 1751 HARBOR BAY PARKWAY, ALAMEDA CA 94502
Tpg Group Holdings (sbs) Advisors, Inc. 10 percent owner C/O TPG GLOBAL, LLC, 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
James G Coulter 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
David Bonderman 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102

Adynxx (Adynxx) Headlines

From GuruFocus

Alliqua Biomedical CEO Provides Update to Shareholders

By Marketwired Marketwired 01-03-2019

Adynxx Reports Third Quarter 2019 Financial Results

By Marketwired Marketwired 11-14-2019

CFO of Alliqua BioMedical Inc Buys 2,500 Shares

By Jennifer Chiou Jennifer Chiou 08-12-2015